{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-049116","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.521072+00:00","generated_at":"2026-06-05T08:05:13.736625+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Madrigal reports Q4 2023 cash of $634M, appoints new CFO, resmetirom PDUFA March 14","bullets":["Appointed Mardi C. Dier as CFO; previously CFO at Portola, Ultragenyx, and Acelyrin.","Resmetirom PDUFA date March 14, 2024; company anticipates first NASH approval.","Cash and marketable securities $634.1M at Dec 31, 2023, up from $358.8M at Dec 31, 2022.","Operating expenses Q4 2023 $117.2M vs $85.3M YoY; full year $380.5M vs $293.6M.","G&A expenses Q4 2023 $46.5M vs $14.6M YoY due to commercial launch preparation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-049116","json":"https://secwatch.observer/filing/0001193125-24-049116.json","markdown":"https://secwatch.observer/filing/0001193125-24-049116.md","text":"https://secwatch.observer/filing/0001193125-24-049116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000119312524049116/0001193125-24-049116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000119312524049116/d743882d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:05:13.736625+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}